Key Takeaways
- • EQT Private Equity, through its EQT XI fund and bidder Crown NL Bidco B.V., agreed to acquire all outstanding QIAGEN shares in an all-cash voluntary public takeover offer at €46.50 per share, valuing QIAGEN at approximately €10.8 billion in enterprise value (about $12.1 billion, including roughly $1.1 billion of net debt).
- • The offer represents a 40.3% premium to the XETRA closing price of €33.15 on July 8, 2026, and a 46.9% premium to the three-month VWAP of €31.66.
- • QIAGEN's Supervisory and Managing Boards unanimously support the transaction and will recommend that shareholders tender their shares.
- • Co-investors Abu Dhabi Investment Authority (via Luxinva S.A.) and CPP Investments (via CPP Investment Board Europe Inc.) participate alongside EQT.
- • Completion is expected in mid-2027, subject to a 50% plus one share minimum acceptance threshold, EGM approval of post-closing measures, and merger control and foreign investment clearances.
Summary
QIAGEN N.V. and the EQT XI fund (EQT Private Equity) have announced an agreement under which Crown NL Bidco B.V. will launch an all-cash voluntary public takeover offer for all outstanding QIAGEN shares at €46.50 per share. The offer values QIAGEN at approximately €10.8 billion in enterprise value, or about $12.1 billion at current exchange rates, including approximately $1.1 billion of net debt. The offer price represents a 40.3% premium to the XETRA closing price of €33.15 on July 8, 2026, the last trading day before market reports surfaced regarding takeover interest from private equity firms, and a 46.9% premium to the three-month volume-weighted average price of €31.66.
The Bidder is indirectly controlled by the EQT XI fund, with further indirect participations held by co-investors Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe Inc., a wholly owned subsidiary of Canada Pension Plan Investment Board (CPP Investments). EQT Private Equity is managed and controlled by affiliates of EQT AB of Stockholm, which the company says manages €354 billion in assets under management.
QIAGEN's Supervisory Board and Managing Board conducted a comprehensive strategic review that included discussions with both strategic and financial parties. The boards unanimously concluded the transaction is in the best interest of the company and its stakeholders. Stephen H. Rusckowski, Chairman of the Supervisory Board, said the deal "offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership." CEO Jonathan M. Pratt said private ownership would allow the company to "move faster" and deploy resources toward its most attractive opportunities. CFO Roland Sackers described EQT as a partner that "shares our strategic priorities and vision for the future."
EQT's healthcare team, led by Michael Bauer, Global Co-Head of Healthcare, and Partner Matteo Thun-Hohenstein, cited EQT's experience in life sciences, with more than 210 healthcare investments and over €30 billion invested globally. Current and former portfolio companies named include SPT Labtech, Galderma, Parexel, Aldevron, Dako and HemoCue. Under the Business Combination Agreement, EQT has committed to support QIAGEN's long-term strategy, brands, R&D, employees and operational footprint, and the company will continue to operate under the QIAGEN name.
Completion is expected in mid-2027. The offer is conditioned on a minimum acceptance threshold of 50% of outstanding share capital plus one share, adoption of resolutions at an Extraordinary General Meeting including the post-closing measures, a separate implementation decision by the boards, and merger control and foreign investment clearances. Post-closing measures would give the Bidder full ownership, with non-tendering shareholders receiving a cash distribution equal to the offer price less applicable withholding taxes, and QIAGEN's listings on the FSE and NYSE would be terminated. If closing has not occurred within 10 months of the announcement because of pending regulatory approvals, QIAGEN may pay an interim dividend of up to $0.47 per share, which would not be deducted from the offer price.
The Bidder is indirectly controlled by the EQT XI fund, with further indirect participations held by co-investors Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe Inc., a wholly owned subsidiary of Canada Pension Plan Investment Board (CPP Investments). EQT Private Equity is managed and controlled by affiliates of EQT AB of Stockholm, which the company says manages €354 billion in assets under management.
QIAGEN's Supervisory Board and Managing Board conducted a comprehensive strategic review that included discussions with both strategic and financial parties. The boards unanimously concluded the transaction is in the best interest of the company and its stakeholders. Stephen H. Rusckowski, Chairman of the Supervisory Board, said the deal "offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership." CEO Jonathan M. Pratt said private ownership would allow the company to "move faster" and deploy resources toward its most attractive opportunities. CFO Roland Sackers described EQT as a partner that "shares our strategic priorities and vision for the future."
EQT's healthcare team, led by Michael Bauer, Global Co-Head of Healthcare, and Partner Matteo Thun-Hohenstein, cited EQT's experience in life sciences, with more than 210 healthcare investments and over €30 billion invested globally. Current and former portfolio companies named include SPT Labtech, Galderma, Parexel, Aldevron, Dako and HemoCue. Under the Business Combination Agreement, EQT has committed to support QIAGEN's long-term strategy, brands, R&D, employees and operational footprint, and the company will continue to operate under the QIAGEN name.
Completion is expected in mid-2027. The offer is conditioned on a minimum acceptance threshold of 50% of outstanding share capital plus one share, adoption of resolutions at an Extraordinary General Meeting including the post-closing measures, a separate implementation decision by the boards, and merger control and foreign investment clearances. Post-closing measures would give the Bidder full ownership, with non-tendering shareholders receiving a cash distribution equal to the offer price less applicable withholding taxes, and QIAGEN's listings on the FSE and NYSE would be terminated. If closing has not occurred within 10 months of the announcement because of pending regulatory approvals, QIAGEN may pay an interim dividend of up to $0.47 per share, which would not be deducted from the offer price.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.